CD8A and melanoma: Non-randomized trial in newly diagnosed glioblastoma patients (67): significantly improved tumor control rates and survival rates in DC vaccine group than in control group; increased proportions of peripheral CD4+ and CD8+ T cells post vaccination compared to control group; in combination with other cell killing modalities in B-cell lymphoma and melanoma patients (57, 68)